Emerging applications of gene transfer in the hematopoietic cancers

Journal of Pediatric Hematology/Oncology

Volumn 19, Issue 1, 1997, Pages 1-6

  Brenner, Malcolm K ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Gene transfer; Hematologic malignancy; Stem cells; Vectors

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; DRUG METABOLIZING ENZYME; PRODRUG;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ARTICLE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG SENSITIVITY; EXPRESSION VECTOR; GENE TRANSFER; GENETIC DISORDER; GENETIC MARKER; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; IMMUNOGENETICS; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS;

GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELLS; HUMANS;

EID: 0030906499     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199701000-00001     Document Type: Article

References (36)

1. Snyder DS, Wu Y, Wang JL, et al. Ribozyme-mediated inhibition of bcr-abl gene expression in Philadelphia chromosome-positive cell line. Blood 1993;82:600-5.
2. Scanlon KJ, Jiao L, Funato T, et al. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci USA 1991;88:10591-5.
3. Ratajczak MZ, Kant JA, Luger SM, et al. In vivo treatment of human leukemia in a SCID mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 1992;89:11823-7.
4. Anderson WF. The ADA human gene therapy clinical protocol. Hum Gene Ther 1990;1:327-62.
5. Rossi JJ. Therapeutic antisense and ribozymes. Br Med Bull 1995; 51:217-25.
6. Zhang Y, Mukhopadhyay T, Donehower LA, Georges RN, Roth JA. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther 1993;4:451-60.
7. Fujiwara T, Grimm EA, Cai DW, Owen-Schaub LB, Roth JA. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 1993;53:4129-33.
8. Wang J, Bucana CD, Roth JA, Zhang W. Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. Cancer Gene Ther 1995;2:9-18.
9. Ram Z, Culver KW, Walbridge S, et al. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 1993;83-8.
10. Wei MX, Tamiya T, Chase M, et al. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther 1994;5:969-78.
11. Knox RJ, Friedlos F, Boland MP. The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Cancer Metastasis Rev 1993;12:195-212.
12. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75: 555-62.
13. Brenner MK, Heslop HE. Graft-versus-host reactions and bone marrow transplantation. Curr Opin Immunol 1991;3:752-7.
14. Melief CJ, Kast WM. Potential immunogenicity of oncogene and tumor supressor gene products. Curr Opin Immunol 1993;5:709-13.
15. Nabel GJ, Nabel EG, Yang ZY, et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90:11307-11.
16. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-102.
17. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD- T cells by B7-transfected melanoma cells. Science 1993;259:368-70.
18. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989;57:503-12.
19. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-6.
20. Fearon ER, Pardoe DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397-403.
21. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-24.
22. Colombo MP, Ferrari G, Stoppacciaro A, et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorogenicity of a murine adenocarcinoma in vivo. J Exp Med 1991;173:889-97.
23. Colombo MP, Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 1994;15: 48-51.
24. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-91.
25. Rooney CM, Smith CA, Ng C, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995;345:9-13.
26. Rosenberg SA. Gene therapy for cancer. JAMA 1992;268:2416-9.
27. Murphy D, Crowther D, Renninson J, et al. A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles. Ann Oncol 1993;4:377.
28. Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987;5:756.
29. Pastan I, Gottesman MM. Multidrug resistance. Annu Rev Med 1991;42:277.
30. Mickisch GH, Licht T, Merlino GT, Gottesman MM, Pastan I. Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency, and toxicity. Cancer Res 1991;51:5417.
31. Mickisch GH, Merlino GT, Galski H, Gottesman MM, Pastan I. Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci USA 1991;88:547.
32. McLachlin JR, Eglitis MA, Ueda K, et al. Expression of a human complementary DNA for the multidrug resistance gene in murine hematopoietic precursor cells with the use of retroviral gene transfer. J Natl Cancer Inst 1990;82:1260.
33. 6-methylguanine methyltransferase (MGMT) protects hematopoietic cells (HC) from nitrosourea (NU)-induced toxicity in vitro and in vivo [abstract]. Blood 1993;82:118.
34. Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993;341:85-6.
35. Rill DR, Santana VM, Roberts WM, et al. Direct demonstration that autologous bone marrow transplantation for solid tumors return a multiplicity of tumorigenic cells. Blood 1994;84:380-
36. Deisseroth AB, Zu Z, Claxton D, et al. Genetic marking shows that Ph- cells present in autologous transplants of chronic myelogene leukemia (CML) contribute to relapse after autologous bone marrrow in CML. Blood 1994;83:3068-76.